Rockwell Medical, Inc. (RMTI)
| Market Cap | 28.35M -17.8% |
| Revenue (ttm) | 67.68M -30.7% |
| Net Income | -5.56M |
| EPS | -0.15 |
| Shares Out | 39.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 354,885 |
| Open | 0.7408 |
| Previous Close | 0.7435 |
| Day's Range | 0.7100 - 0.7435 |
| 52-Week Range | 0.7100 - 2.1000 |
| Beta | 1.65 |
| Analysts | Buy |
| Price Target | 3.00 (+316.96%) |
| Earnings Date | May 7, 2026 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic a... [Read more]
Financial Performance
In 2025, Rockwell Medical's revenue was $69.26 million, a decrease of -31.76% compared to the previous year's $101.49 million. Losses were -$5.47 million, 599.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for RMTI stock is "Buy." The 12-month stock price target is $3.0, which is an increase of 316.96% from the latest price.
News
Rockwell Medical renews and extends purchase agreement with aQua Dialysis
Rockwell Medical (RMTI) announced that the Company has renewed and extended its product purchase agreement with aQua Dialysis a leading independent provider of in-center hemodialysis and home dialysis...
Rockwell Medical Renews Product Purchase Agreement with aQua Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply aQua Dialysis with liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialy...
Rockwell Medical signs new product purchase agreement with Heritage Dialysis
Rockwell Medical (RMTI) announced that the company entered into a three-year product purchase agreement with Heritage Dialysis, a Michigan-based family-owned company comprised of dialysis professional...
Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply Heritage Dialysis with a portfolio of hemodialysis products including PureCart, RenalPure, SteriLyte and ot...
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw improved gross margin and stable gross profit despite lower sales, with positive trends in adjusted EBITDA and net income. Guidance for 2026 projects $70–$75M in sales, 18–22% gross margin, and positive cash flow, supported by operational efficiencies and international growth.
Rockwell Medical Earnings release: Q1 2026
Rockwell Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rockwell Medical Quarterly report: Q1 2026
Rockwell Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rockwell Medical Slides: Q1 2026
Rockwell Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Rockwell Medical reports Q1 adjusted EPS (1c) vs. (1c) last year
Reports Q1 revenue $17.3M vs. $18.9M last year. “Our financial and operational performance in the first quarter 2026 builds on the positive trajectory we have established across our key financial…
Rockwell Medical sees 2026 revenue $70.0M-$75.0M, consensus $73.77M
Sees 2026 adjusted EBITDA $1.0M-$2.0M.
Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical 2026 Guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA...
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026.
Rockwell Medical price target lowered to $2 from $2.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rockwell Medical (RMTI) to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites the company’s “more modest”…
Rockwell Medical price target lowered to $4 from $5 at Maxim
Maxim lowered the firm’s price target on Rockwell Medical (RMTI) to $4 from $5 and keeps a Buy rating on the shares. The firm cites the company’s Q4 results with…
Rockwell Medical Earnings Call Transcript: Q4 2025
Profitability was maintained on an adjusted EBITDA basis in 2025, with gross margin reaching historic highs in Q4 and a strengthened cash position. Expanded customer agreements and rapid response to supply chain disruptions drove growth, with 2026 guidance projecting further profitability.
Rockwell Medical Annual report: Q4 2025
Rockwell Medical has published its Q4 2025 annual report on March 26, 2026.
Rockwell Medical Earnings release: Q4 2025
Rockwell Medical released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
Rockwell Medical Slides: Investor presentation
Rockwell Medical has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Rockwell Medical reports Q4 EPS 4c vs. 2c last year
Reports Q4 revenue $18.3M vs. $24.7M last year. “2025 was a year of transition for Rockwell Medical (RMTI). We successfully navigated changes in our customer base, purchase volumes, and distribution…
Rockwell Medical sees 2026 adjusted EBITDA $1M-$2M
Sees 2026 operating cash flow positive.
Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025.
Rockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the fourth quarter and full-year ended December 31, 2025 on Thursday, March 26, 2026.